Baseline neutrophilia, derived neutrophil‐to‐lymphocyte ratio (dNLR), platelet‐to‐lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
暂无分享,去创建一个
V. Adamo | A. Giordano | A. Battaglia | G. Ricciardi | T. Franchina | A. Russo | R. Berenato | A. Scimone
[1] Ray-Jade Chen,et al. The multifaceted link between inflammation and human diseases , 2018, Journal of cellular physiology.
[2] W. Jochum,et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. , 2017, Lung cancer.
[3] N. Sharma,et al. Prognostic potential of neutrophil-to-lymphocyte ratio and lymphocyte nadir in stage III non-small-cell lung cancer. , 2017, Future oncology.
[4] C. Fan,et al. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. , 2017, Cancer research.
[5] F. Hodi,et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development , 2017, Nature Reviews Clinical Oncology.
[6] N. Bhooshan,et al. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy. , 2017, The oncologist.
[7] Y. Erdoğan,et al. Prognostic Value of the Neutrophil to Lymphocyte Ratio (NLR) in Lung Cancer Cases , 2017, Asian Pacific journal of cancer prevention : APJCP.
[8] C. Langer,et al. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer. , 2017, Lung cancer.
[9] Robert Ford,et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.
[10] J. Borgia,et al. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer , 2017, BMC Cancer.
[11] A. M. Houghton,et al. Neutrophils dominate the immune cell composition in non-small cell lung cancer , 2017, Nature Communications.
[12] Carlos Barrios,et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial , 2017, The Lancet.
[13] Charles Ferté,et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 , 2016, Clinical Cancer Research.
[14] S. Aebi,et al. A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing , 2016 .
[15] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[16] L. Nardo,et al. Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma. , 2016, The Journal of clinical investigation.
[17] L. Chin,et al. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. , 2016, Cancer discovery.
[18] J. de-Torres,et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. , 2016, Lung cancer.
[19] Seok-Hyun Kim,et al. Clinical significance of the preoperative platelet count and platelet-to-lymphocyte ratio (PLT-PLR) in patients with surgically resected non-small cell lung cancer , 2016, Oncotarget.
[20] Y. Shentu,et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial , 2016, The Lancet.
[21] P. Ascierto,et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[22] W. Xiong,et al. Prognostic value of platelet to lymphocyte ratio in non-small cell lung cancer: evidence from 3,430 patients , 2016, Scientific Reports.
[23] C. Rudin,et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[24] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[25] Ming-Sound Tsao,et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[26] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[27] Razelle Kurzrock,et al. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy , 2015, Molecular Cancer Therapeutics.
[28] V. Gebski,et al. Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia , 2013, Journal of Translational Medicine.
[29] C. Garlanda,et al. Tumor associated macrophages and neutrophils in tumor progression , 2013, Journal of cellular physiology.
[30] Sven Diederichs,et al. The hallmarks of cancer , 2012, RNA biology.
[31] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[32] P. Murphy. The Neutrophil , 1976, Springer US.